ZyVersa Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

ZyVersa TherapeuticsDer Gewinn pro Aktie wird voraussichtlich um 143.9% pro Jahr wachsen.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

143.9%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.3%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	None
Zuletzt aktualisiert	n/a

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:ZVSA - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
9/30/2024	N/A	-29	-9	-9	N/A
6/30/2024	N/A	-22	-9	-9	N/A
3/31/2024	N/A	-106	-8	-8	N/A
12/31/2023	N/A	-106	-9	-9	N/A
9/30/2023	N/A	-88	-10	-10	N/A
6/30/2023	N/A	-98	-9	-9	N/A
3/31/2023	N/A	-14	-9	-9	N/A
12/31/2022	N/A	-14	-5	-5	N/A
9/30/2022	N/A	-21	-2	-2	N/A
6/30/2022	N/A	-10	-2	-2	N/A
3/31/2022	N/A	-10	-3	-3	N/A
12/31/2021	N/A	-8	-5	-5	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Unzureichende Daten, um festzustellen, ob das prognostizierte Gewinnwachstum von ZVSA über der Sparquote liegt (2.6%).

Ertrag vs. Markt: Unzureichende Daten, um festzustellen, ob die Gewinne von ZVSA schneller wachsen werden als der Markt US

Hohe Wachstumserträge: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von ZVSA in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von ZVSA schneller wachsen werden als der Markt von US.

Hohe Wachstumseinnahmen: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Einnahmen von ZVSA schneller wachsen werden als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ZVSA in 3 Jahren voraussichtlich hoch sein wird

ZyVersa Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100

ZyVersa Therapeutics, Inc. Forms New Scientific Advisory Board

ZyVersa Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $1.397396 million.

ZyVersa Therapeutics, Inc., Annual General Meeting, Oct 29, 2024

ZyVersa Therapeutics, Inc. Announces Publish Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation

ZyVersa Therapeutics, Inc. Announces IRB Approval of Phase 2A Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator VAR 200 in Patients with Diabetic Kidney Disease

ZyVersa Therapeutics Receives Letter of Reprimand from Nasdaq in Accordance with Nasdaq’s Listing Rule 5810(c)(4)

ZyVersa Therapeutics Receives Approval from Nasdaq to Transfer the Listing of Common Stock from the Nasdaq Global Market to the Nasdaq Capital Market

ZyVersa Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $4.99964 million.

Nasdaq Issues A Letter to ZyVersa Therapeutics, Inc. Regarding Listing Rule 5810(c)(3)(A)(iii)

Nasdaq Issues A Letter to ZyVersa Therapeutics, Inc. Regarding Listing Rule 5810(c)(3)(A)(iii)

High number of new and inexperienced directors

ZyVersa Therapeutics, Inc. has filed a Follow-on Equity Offering.

ZyVersa Therapeutics, Inc. has filed a Follow-on Equity Offering.

ZyVersa Therapeutics, Inc. Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating that Inflammasome ASC Inhibitor IC 100 Attenuates Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing Neuroprotection

ZyVersa Therapeutics, Inc. Announces Research Published in the Peer-Reviewed Journal Diabetes Reinforcing IC 100's Rationale for Inhibiting ASC to Attenuate Damaging Inflammation Associated with Serious Conditions Such as Obesity-related Heart Disease

ZyVersa Therapeutics, Inc. Announces New Peer-Reviewed Publication Reinforcing the Rationale for Inhibiting ASC Specks with IC 100 to Attenuate Spread of Inflammation into Surrounding Tissues

Zyversa Therapeutics Announces Research Published in the Journal of Clinical Investigation Reinforcing Ic 100’s Rationale for Inhibiting ASC Specks to Attenuate Spread of Inflammation into Surrounding Tissues

Zyversa Therapeutics, Inc. Announces Research Published in Frontiers in Immunology Reinforcing Ic 100'S Rationale for Inhibiting Multiple Inflammasomes to Control Inflammation in Various Inflammatory Diseases

ZyVersa Therapeutics, Inc. Receives Non-Compliance Letter from Nasdaq

ZyVersa Therapeutics, Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2023

ZyVersa Therapeutics, Inc., Annual General Meeting, Oct 31, 2023

ZyVersa Therapeutics, Inc. announced delayed 10-Q filing

ZyVersa Therapeutics, Inc. Announces European Patent Granted for ZyVersa Therapeutics' Lead Asset, Cholesterol Efflux Mediator™? VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease

ZyVersa Therapeutics, Inc. Announces Publication in Journal of the American Heart Association Linking NLRP3 Inflammasomes with Calcification in Arterial Disease

ZyVersa Therapeutics Receives Non-Compliance Letter Form Nasdaq

European Patent Office to Grant Zyversa Therapeutics' Patent Application for Cholesterol Transport Mediator™? Var 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease

ZyVersa Therapeutics, Inc. Announces Changes to Board of Directors

ZyVersa Therapeutics, Inc. Appoints Dr. Pablo Guzman as Chief Medical Officer and Senior Vice President of Medical Affairs

Less than half of directors are independent

ZyVersa Therapeutics, Inc. Announces Executive Changes

ZyVersa Therapeutics, Inc. Adds Two Esteemed Leaders to Its Renal Scientific Advisory Board

High number of new directors

No independent directors

ZyVersa Therapeutics, Inc. completed the acquisition of Larkspur Health Acquisition Corp. (NasdaqGM:LSPR) from Larkspur Health LLC, A.G.P. / Alliance Global Partners Corp. and others in a reverse merger transaction.

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken